Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;36(1):74-84.
doi: 10.1080/14756366.2020.1839446.

Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms

Affiliations

Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms

Samir Mehndiratta et al. J Enzyme Inhib Med Chem. 2021 Dec.

Abstract

A series of 3-subsituted quinolinehydroxamic acids has been synthesised and evaluated for their effect on human lung cancer cell line (A549), human colorectal cancer cell line (HCT116) and HDAC isoforms 1, 2, 6, and 8. The results indicated that substitution at C3 of quinoline is favoured for HDAC6 selectivity. Two compounds (25 and 26) were also found to be potent anti-proliferative compounds with IC50 values ranging from 1.29 to 2.13 µM against A549 and HCT116 cells. These compounds displayed remarkable selectivity for HDAC6 over other HDAC isoforms with nanomolar IC50 values. Western blot analysis revealed that compounds of this series activate apoptotic caspase pathway as indicated by cleavage of caspase 3, 8, and 9 and also increase phosphorylated H2AX thus inducing DNA double strand fragmentation in a concentration dependent manner. Flow cytometric analysis also displayed a dose dependent increase of cell population in sub G1 phase.

Keywords: HDAC; Quinoline; acrylamide; colon cancer; hydroxamic acid; lung cancer.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Various examples of histone deacetylase inhibitors (15).
Figure 2.
Figure 2.
Previously synthesised quinoline-containing HDAC inhibitors (6–13).
Figure 3.
Figure 3.
Synthetic 3-substituted quinolinehydroxamic acids (14–29).
Scheme 1.
Scheme 1.
Synthetic Approaches to Compounds 14–29a. aReagents and conditions: (a) NXS, acetic acid, 110 oC, 30–61%; (b) phenylboronic acid, Pd(OAc)2, PPh3, Na2CO3, THF, H2O, MW, 90 oC, 90%; (c) CuI, 1,10-phenanthroline, Cs2CO3, MeOH, toluene, MW, 70 oC, 57%; (d) for 32–36: i. Fe powder, 1N HCl(aq), EtOH (or MeOH), reflux; ii. methyl 4-formylbenzoate, NaBH(OAc)3, DCM, 40 oC; for 3747: 33, boronic acids, Pd(PPh3)4, TBAB, 2M K2CO3(aq), dioxane, reflux, 35–69%; (e) i. 1N LiOH(aq), dioxane, rt; ii. NH2OTHP, HBTU, DMF, TEA, rt; iii. 10% TFA(aq), MeOH, rt, 28–55%.
Figure 4.
Figure 4.
Effect of treatment with compound 17, 25, and 26 at three different doses (0.25 µM, 5 µM, and 10 µM) on cleavage of caspase 3, 8, and 9 and PARP. Increased expression of gamma H2AX, a phosporylated form of H2AX, indicates increased DNA double strand fragmentation of A549 cells treated for 48 h in a dose- dependent manner.
Figure 5.
Figure 5.
(A) A549 cells were treated with or without 17, 25, and 26 (0.25, 0.5, 10 μM) for 48 h and were analysed by flow cytometry for cell cycle distribution. (B) After starvation for 24 h, A549 cells were then treated with compounds for the indicated time. After labelling with propidium iodide, DNA content was analysed by flow cytometry. (C) Quantification of cell population in Sub G1, G0/G1, S and G2/M phase. In A, B, and C, percent of cells = 100%.
Figure 6.
Figure 6.
Docking of compound 17 (green) in the binding site of HDAC6 (PDB ID: 6CGP).

Similar articles

Cited by

References

    1. Barnes P, Adcock IM, Ito K.. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Resp J 2005;25:552–63. - PubMed
    1. Dokmanovic M, Clark C, Marks PA.. Histone deacetylase inhibitors: overview andperspectives. Mol Cancer Res 2007;5:981–9. - PubMed
    1. Adcock IM. HDAC inhibitors as anti‐inflammatory agents. Br J Pharmacol 2007;150:829–31. - PMC - PubMed
    1. Adcock IM, Ito K, Barnes PJ.. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD 2005;2:445–55. - PubMed
    1. (a) Mehndiratta S, Pan SL, Kumar S, et al. . Indole-3-ethylsulfamoylphenylacrylamides with potent anti-proliferative and anti-angiogenic activities. Anticancer Agents Med Chem 2016;16:907–13. - PubMed
    2. (b) Huang YC, Huang FI, Mehndiratta S, et al. . Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis. Oncotarget 2015;6:18590–601. - PMC - PubMed

MeSH terms